The FDA has approved Bayer’s Jivi for use in children 7 years of age and older with hemophilia A, a bleeding disorder that is caused by a lack or low level of clotting factor VIII. Hemophilia A is caused by mutations in the F8 gene , according to the CDC.

Jivi is a recombinant DNA-derived, extended half-life factor VIII concentrate and is already approved to treat patients 12 years of age and older with hemophilia A. Jivi was engineered with polyethylene glycol (PEG), which increases FVIII’s stability and allows for less frequent dosing.

The recommended initial dosage of Jivi for both adults and adolescents is 30-40 IU/kg twice weekly with the ability to dose every five days. The dosing can be adjusted based on bleeding episodes.

Jivi is 100% covered under the Medicare medical benef

See Full Page